Senseonics initiated with an Outperform at Mizuho

Mizuho initiated coverage of Senseonics (SENS) with an Outperform rating and $2 price target citing positive survey data for continued continuous glucose monitoring category adoption along with “bullish physician feedback” for the company’s flagship Eversense 365 adoption over the next several years. Physician checks point toward well over 100 basis points of total U.S. share gains for Eversense 365 over the next several years, the analyst tells investors.